Welcome to Tetherex Pharmaceuticals
At Tetherex, we are committed to advancing the understanding of inflammation in various disease processes and developing novel products to treat inflammatory and infectious diseases and cancer. Our mission is focused on helping patients who suffer these afflictions enjoy better and longer lives. Our pioneering work on the molecular mechanisms of inflammation has led to breakthroughs in novel therapeutic candidates for inflammatory diseases and positioned Tetherex with strong scientific underpinnings. Our employees are committed to the highest standards of integrity and excellence in medical research.
Tetherex Pharmaceuticals, a clinical-stage drug development company, was formed in 2014 as a spin-off of Selexys Pharmaceuticals to develop novel first-in-class therapeutics targeting cell adhesion proteins in inflammatory and oncologic diseases. Based on pioneering scientific work on the molecular mechanisms of cell adhesion and inflammation by our founding scientists, Tetherex is advancing new breakthrough therapeutics. Our lead selectin inhibitor clinical program is focused on a functionally blocking anti-PSGL-1 antibody called SelK2 which is currently under development for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Tetherex has also acquired an exclusive worldwide license from Mayo Clinic for the development and commercialization of a novel single-cycle adenovirus vaccine platform which is currently under investigation as a vaccine for COVID-19. We invite you to explore our website and learn more about our highly experienced management team and our clinical development programs.